RT Journal Article
SR Electronic
T1 Pilot Comparison of <sup>18</sup>F-FP-R<sub>0</sub>1-MG-F2 and <sup>18</sup>F-FDG PET in Patients with Pancreatic Cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1004
OP 1004
VO 62
IS supplement 1
A1 Nakamoto, Ryusuke
A1 Duan, Heying
A1 Ferri, Valentina
A1 HATAMI, NEGIN
A1 Goel, Mahima
A1 Kimura, Richard
A1 Wardak, Mirwais
A1 Haywood, Tom
A1 Shen, Bin
A1 Park, Walter
A1 Iagaru, Andrei
YR 2021
UL http://jnm.snmjournals.org/content/62/supplement_1/1004.abstract
AB 1004Purpose: A new cystine knot PET tracer, 18F-FP-R01-MG-F2, has been shown to selectively bind to human integrin αvβ6. This integrin cell surface receptor is over-expressed in pancreatic cancer, as well as other cancers. Here, we compared the tumor uptake of 18F-FP-R01-MG-F2 with 18F-FDG in patients with pancreatic cancer. Methods: Seven patients (1 man, 6 women) with histologically confirmed pancreatic cancer were prospectively enrolled between March 2017 and November 2019. All patients underwent an 18F-FP-R01-MG-F2 PET/CT scan and 18F-FDG PET/CT scan within 3 weeks of each other. Maximum standardized uptake values (SUVmax), mean SUV (SUVmean), and tumor-to-normal tissue (T/N) ratios of known or suspected cancer lesions detected by both 18F-FP-R01-MG-F2 and 18F-FDG PET were compared on a per-lesion based analysis. Results: 18F-FP-R01-MG-F2 PET detected known pancreatic tumors in all 7 patients. Of the four patients with lymph node metastases confirmed by surgery (n = 1) or suspected by contrast-enhanced CT (n = 3), each PET scan detected lymph node metastases in three patients but failed to detect them in one different patient. Compared with 18F-FDG, 18F-FP-R01-MG-F2 had significantly higher T/N ratios in liver metastases (n = 27, 4.3 ± 1.4 vs. 1.5 ± 0.3, P &lt; 0.001), but no significant differences in pancreatic tumors (n = 7, 1.7 ± 0.8 vs. 2.4 ± 0.7, P &gt; 0.30). In two patients with lung metastases without significant 18F-FDG uptake, 18F-FP-R01-MG-F2 showed significant uptake, although T/N ratios could not be compared due to small sample size. There was weak correlation between uptake values from 18F-FP-R01-MG-F2 and 18F-FDG (ρ = 0.40 &amp; ρ = 0.30 for SUVmax and SUVmean, respectively). Conclusions: Staging of pancreatic cancer with 18F-FP-R01-MG-F2 PET is feasible. 18F-FP-R01-MG-F2 PET was superior to 18F-FDG PET in detecting lung and liver metastases and had a higher lesion conspicuity (T/N ratio) for liver metastases. The weak correlation between 18F-FP-R01-MG-F2 and 18F-FDG uptake suggests that the biological information provided by each PET tracer is different.